Matapos ianunsyo ang kanilang "safe" at "effective" antidote, inialok ng Russia sa Pilipinas ang COVID-19 vaccine nito--at positibo naman ang tugon ng nahuli sa mungkahing ito.
Ads
Sa isang press briefing kamakailan, sinabi ni Russian Ambassador Igor Khovaev na layunin nilang magsagawa ng clinical trials at magtayo ng vaccine production hub sa Pilipinas kung aaprubahan ito ng gobyerno.
"We are ready to combine our efforts, we are ready to make the necessary investments with our Filipino partners and we are ready to share our technologies simply because we want to build a robust partnership between our two nations," ani Khovaev.
Pagpapatuloy niya, hindi sila nangangako, kung 'di nagbibigay ng mungkahi base sa kung ano ang alam nila at kung ano na ang kanilang nagawa.
Ads
Sponsored Links
Wika ng opisyal, sa kasalukuyan ay maganda ang itinatakbo ng series of trials na isinasagawa ng grupo ng volunteers sa Russia.
"We don't make promises. We make suggestions based on what we already know and what we have done," aniya. "We already have the vaccine so all necessary bureaucratic procedures in order to get an official administrative approval might be completed until mid-August. The vaccine is effective and safe."
Positibo naman ang tugon ng Department of Foreign Affairs (DFA) sa nasabing proposal.
“The DFA conveys its appreciation for Russia’s willingness to assist the Philippines in its fight against COVID-19, as well as its offer to supply the SARS-COV-2 vaccine developed by N.F. Gamaleya of the Ministry of Health of the Russian Federation,” saad nito sa isang statement.
Narito ang mga dapat mong malaman tungkol sa bakuna na idine-develop ngayon ng Russia:
Ilang araw ba ang bibilangin para ang isang taong naging positibo sa COVID-19 ay masasabing hindi na nakakahawa?
Ayon sa World Health Organization, ang Pilipinas ang may 'fastest-growing number of new COVID-19 cases' sa higit 20 bansa at teritoryo sa Western Pacific Region.
Ngayong wala pang gamot o vaccine sa COVID-19, mahalaga ang epektibong contact tracing. Ito ang naging strategy ng Vietnam, Taiwan, at New Zealand kaya napigilan nila ang pagkalat ng sakit. Paano nga ba ginagawa ang contact tracing dito sa Pilipinas? Kumusta ang mga proseso? Alamin natin sa video na ito!
Ads
Hindi na raw po nakakahawa ang mga pasyenteng nagkaCOVID-19 at sampung (10) araw ng walang sintomas kaya ang sabi ng Department of Health, hindi na sila kailangang itest ulit. Base raw ito sa mga bagong scientific evidence. Panoorin ang video report.
Ads
Sponsored Links
Samantala, pinag-aaralang bawasan ang additional quarantine days ng COVID-19 patient na discharge na sa hospital ayon sa Department of Health. Sabi ni DOH Spokesperson Undersecretary Maria Rosario Vergeire, lumabas kasi sa pag-aaral ng mga eksperto na hindi na nakakahawa ang taong may COVID-19 sa ikasampung araw niyang maysakit.
Iyan daw ang dahilan sa pagbabago ng kanilang protocol na hindi na kailangag itetest ang pasyente bago idischarge sa hospital o quarantine facility. Kung kinakailangang irekomenda ng mga eksperto ang additional quarantine days ng pasyente pagkalabas ng hospital ay posibleng babawasan ito ng hanggang sa 7 araw mula sa 14 days. Nilinaw naman ng DOH na nanatiling 14 days ang quarantine period sa mga probable at suspected COVID-19 cases. Pitong simpleng hakbang upang maprotektahan ang sarili at ang iba laban sa COVID-19
Ang coronavirus disease (COVID-19) ay isang nakahahawang sakit na dulot ng bagong coronavirus. Karamihan sa mga taong magkakaroon ng impeksyon ay makararanas ng hindi malalang sintomas at gagaling. Ngunit ang iba ay makararanas ng malubhang sakit, lalo na sa mga matatanda at mga may dati nang karamdaman. Narito ang ilang mga simpleng hakbang na maaari mong gawin upang maprotektahan ang kalusugan mo at ng iba.
Ang mga payong ito ay maaaring sundin ng lahat, ngunit napakahalaga ng mga ito kung ikaw ay nakatira sa lugar na may COVID-19. 1. Hugasan nang madalas ang iyong mga kamayUgaliin ang puspusang paglinis ng mga kamay gamit ang hand sanitizer na may alkohol o hugasan gamit ang sabon at tubig.
Bakit? Lagi nating ginagamit ang ating mga kamay upang hawakan ang mga bagay na maaaring kontaminado. Maaaring hindi natin namamalayan na maghawak natin ng ating mukha, nailipat na ang virus sa mata, ilong at bibig at nahawahan na tayo. Namamatay ang mga virus na maaaring nasa iyong kontaminadong kamay, kasama na ang bagong coronavirus, sa pamamagitan ng paghuhugas ng kamay gamit ang sabon at tubig o paggamit ng hand sanitizer na may alkohol.
2. Iwasan ang paghawak sa iyong mata, ilong at bibigMadalas nating hinahawakan ang ating kamay nang hindi namamalayan. Maging mapagmatyag tungkol dito, at iwasan ang paghawak sa iyong mata, ilong at bibig.
Bakit? Maraming hinahawakan ang mga kamay at maaari itong makakuha ng mga virus. Kapag kontaminado na ang kamay, naililipat ang virus sa mata, ilong at bibig at maaaring pumasok sa katawan at magdulot ng sakit.
3. Takpan ang iyong ubo at bahingSiguraduhing ikaw, at ang mga tao sa paligid mo, at sumusunod sa tamang respiratory hygiene. Ibig sabihin nito ay ang pagtakip ng bibig at ilong gamit ang loob ng siko o tisyu kapag uubo o babahing. Agad na itapon ang gamit na tisyu sa basurahang may takip at maghugas ng kamay.
Bakit? Kung ang isang tao ay uubo o babahing, tumatalsik ang maliit na droplet mula sa ilong at bibig na maaaring may virus. Sa pagtakip ng iyong ubo o bahing, naiiiwasan ang pagkalat ng mga virus at mikrobyo sa iba. Sa paggamit ng loob ng siko o tisyu – at hindi iyong kamay – sa pag-ubo o pagbahing, naiiwasan ang paglipat ng kontaminadong droplet sa iyong kamay. Dahil dito, napipigilan ang paglipat ng virus sa tao o bagay. 4. Iwasan ang matatao na lugar at malapit na pakikipagsalamuha sa taong may lagnat o uboIwasan ang matataong lugar, lalo na kung and iyong edad ay 60 pataas o may dati nang karamdaman gaya ng altapresyon, diyabetis, sakit sa puso at baga o kanser. Panatilihin ang hindi bababa sa 1 metrong pagitan mula sa iyo at sa kung sinumang may lagnat o ubo.
Bakit? Pangunahing kumakalat ang COVID-19 sa pamamagitan ng droplet na lumabas mula sa bibig o ilong kapag umubo o bumahing ang isang tao. Sa pag-iwas sa mga matataong lugar, nilalayo mo ang iyong sarili (ng hindi bababa sa 1 metro) mula sa mga taong maaaring may COVID-19 o sinumang may iba pang may sakit.
5. Manatili sa bahay kung ikaw ay may sakit
Manatili sa bahay kung ikaw ay may nararamdamang sakit, kahit sinat at ubo lang.
Bakit? Sa pagpanatili sa loob ng bahay at hindi pagpunta sa trabaho o iba pang lugar, gagaling ka ng mas mabilis at maiiwasan ang pagkalat ng sakit sa ibang tao. 6. Kung ikaw ay may lagnat, ubo at hirap sa pag-hinga, magpakonsulta agad – ngunit tawagan mo muna ang health facilityKung ikaw ay may lagnat, ubo at hirap sa pag-hinga, magpakonsulta ng maaga – kung kakayanin, tumawag muna sa ospital o health center para masabihan ka kung saan ka pupunta.
Bakit? Makatutulong ito upang masiguro na tama ang payong mabibigay sayo, ikaw ay maituro sa tamang health facility, at maiwasan mong makahawa sa iba.
7. Kumuha ng impormasyon sa mapagkakatiwalaang awtoridad
Alamin ang pinakabagong impormasyon tungkol sa COVID-19 mula sa mapagkakatiwalaang artoridad. Siguraduhing ang impormasyon ay mula sa maaasahang mga tagapagsalita – ang Department of Health, World Health Organization (WHO), o iyong lokal na health worker. Dapat ay alam ng lahat ang sintomas – sa karamihan ay nagsisimula ang COVID-19 sa lagnat at tuyong ubo.
Bakit? Ang lokal at pambansang awtoridad ang may alam tungkol sa pinakabagong impormasyon kung kumakalat na ba ang COVID-19 sa iyong lugar. Sila ang mas nakakaalam kung anong tamang payo na dapat ibigay sa iyong lugar, upang maprotektahan ng mga tao ang kanilang sarili.
Base sa WHO, wala pang kumpiramadong oras kung gaano nagtatagal o nagsu-survive ang virus ng COVID-19 sa mga bagay o kagamitan. Subalit maaaring tulad ito ng ibang coronaviruses. Ipinapakita sap ag-aaral na ang coronaviruses ay maaaring mag-survive sa mga bagay o kagamitan sa loob ng maiksing oras hanggang sa ilang mga araw depende sa iba’t ibang kondisyon (hal. Uri ng kagamitan, temperature, at humidity sa kapaligiran).
Ito ay naipapasa ng tao-sa-tao sa pamamagitan ng pagsagap ng mga malilit na talsik ng laway mula sa pagsasalita, pagbahing, o pag-ubo ng isang taong may COVID-19. Ito ay karaniwang nangyayari sa mga taong may malapitang pakikisalamuha sa may sakit – tulad ng mga kapamilya at healthcare workers kaya mariing pinapayo na panatilihin ang isang metrong layo sa mga taong may sintomas tulad ng pag-ubo at pagbahing.
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead’s drug Remdesivir.
UPDATED:
Ads
Ads
Sponsored Links
The University of Chicago Medicine Hospital recruited a total of 125 people with COVID-19 into Gilead’s two Phase 3 clinical trials. Most of those people, 113 had severe disease. All of the patients have been treated with daily infusions of Remdesivir. The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died.
Remdesivir is causing "rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week" in patients at a Chicago hospital
Stat News report: "The best news is that most of our patients have already been discharged, which is great. We've only had two patients perish. Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn't have to be 10 days." said Professor Mullane. “It’s always hard,” she said, because the severe trial doesn’t include a placebo group for comparison. “But certainly when we start [the] drug, we see fever curves falling,” she said. “Fever is now not a requirement for people to go on trial, we do see when patients do come in with high fevers, they do [reduce] quite quickly. We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well.”
What is REMDESIVIR?
It is also one of the 4 drugs being use under WHO Solidarity trials. Remdesivir is an antiviral medication; a nucleotide analog, specifically an adenosine analogue, which inserts into viral RNA chains, causing their premature termination. It is being studied during 2020 as a possible post-infection treatment for COVID-19 illness.
There’s only one drug right now that we think may have real efficacy,” Bruce Aylward of the World Health Organization said last month. “And that’s Remdesivir.”
Coronavirus patients around the world have been rushing to join Remdesivir studies that opened in hospitals in the last few weeks
Gilead says in a fact sheet about Remdesivir the drug Remdesivir was invented by Gilead building on more than a decade of our research. Over that time, our research
scientists have explored the compound for multiple potential uses to help address urgent and unmet medical needs
around the world, including Ebola, SARS, Marburg, MERS and most recently COVID-19. O ur antiviral expertise is the
result of more than 30 years of research and the investment of billions of dollars in research and development.
Gilead’s antiviral work reflects its commitment to collaborating with the global health community and advancing
potential treatments that may help in the global response to public health emergencies.
Remdesivir is an investigational new drug created by Gilead. The research that led to remdesivir began as early as 2009,
with research programs under way in hepatitis C (HCV) and respiratory syncytial virus (RSV). We continued to explore
various uses for remdesivir following its discovery, including antiviral profiling in 2013 and early 2014 that suggested the
potential for remdesivir to have broad spectrum antiviral activity. Gilead’s ground-breaking research has led to an expansive library of compounds invented by Gilead that includes remdesivir. This archive of molecules can be accessed and tested against new viruses as they emerge. Our chemists continually
work to invent new compounds, and Gilead has invested resources and time over decades so that even when a molecule
initially seems unpromising, it may yet one day save lives.
By working in collaboration with both academic institutions and U.S. government agencies, we have been able to bring
together disease experts to help expand knowledge of the antiviral profile of remdesivir against emerging viruses, including
Ebola, SARS, Marburg, and MERS through in vitro studies and in vivo studies in animal models. Testing of remdesivir against
the virus that causes COVID-19 is ongoing COVID-19
In January 2020, when a new pneumonia-like illness in China was identified as a coronavirus, Gilead moved quickly to determine whether remdesivir could play a role in responding to the growing public health threat that subsequently became known
as COVID-19. Gilead’s preclinical data suggested that testing remdesivir against COVID-19 should take place immediately. • Gilead’s team of virologists quickly generated the preclinical
data to characterize remdesivir’s activity against the new
COVID-19 virus and to determine the potential benefit of
further testing. • In January 2020, Gilead provided remdesivir to the China
CDC to test the compound against isolates of the virus that
causes COVID-19 through their independent antiviral assays.
Gilead provided remdesivir to U.S. academic institutions in
February 2020 for similar testing. Results are expected soon. • In February 2020, Gilead began supporting multiple
clinical trials to evaluate the safety and efficacy of remdesivir
as a potential treatment for COVID-19. • Gilead donated study drug and provided scientific input
for two clinical trials coordinated by the China-Japan
Friendship Hospital in China, which began enrolling patients
in early to mid- February. • Gilead donated drugs and provided scientific input for a
NIAID-initiated global clinical trial of remdesivir in late February, including the first site to enroll patients in the United States. • In late February, Gilead initiated its own two Phase 3
studies of remdesivir, which will enroll patients in countries
globally with high numbers of diagnosed COVID-19 cases.
These studies began enrolling patients in March 2020 and
will evaluate two dosing durations of remdesivir. • Gilead has provided input on the design of both WHO’s global
Solidarity trial and the INSERM-sponsored DisCoVeRy trial in
Europe. These trials have already initiated and will expand
to additional countries over the coming months. Gilead has
committed to providing remdesivir to support these studies,
which will be conducted in more than 70 countries worldwide. • In anticipation of potential future needs, we have accelerated
manufacturing timelines to increase our available supply as
rapidly as possible. We are doing this before knowing whether
remdesivir will be determined to be safe and effective to treat
patients with COVID-19
Tenetest ng WHO ang apat na mga gamot na ito na posibleng makatulong laban sa Corona Virus o COVID19. Kasama ang Pilipinas sa team ng Solidarity na nag-aaral at tutuklas kung alin sa mga gamot na ito ang mabisang magpapagaling ng mga apektado ng pandemic na ito.
WHO announced that it would be conducting the trial, called SOLIDARITY, to see if the experimental drugs can curb the coronavirus pandemic. Isa na ang Pilipinas sa mga bansang nakiki-isa sa isinasagawang solidity trial ng World Health Organization (WHO) na may layuning makatuklas ng lunas laban sa coronavirus disease.
Ads
WHO is focusing on what it says are the four most promising therapies: an experimental antiviral compound called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of two HIV drugs, lopinavir, and ritonavir; and that same combination plus interferon-beta, an immune system messenger that can help cripple viruses. Some data on their use in COVID-19 patients have already emerged—the HIV combo failed in a small study in China—but WHO believes a large trial with a greater variety of patients is warranted.
Ads
Sponsored Links
Remdesivir
The new coronavirus is giving this compound a second chance to shine. Originally developed by Gilead Sciences to combat Ebola and related viruses, remdesivir shuts down viral replication by inhibiting a key viral enzyme, the RNA-dependent RNA polymerase.
Researchers tested remdesivir last year during the Ebola outbreak in the Democratic Republic of the Congo, along with three other treatments. It did not show any effect. (Two others did.) But the enzyme it targets is similar in other viruses, and in 2017 researchers at the University of North Carolina, Chapel Hill, showed in test tube and animal studies that the drug can inhibit the coronaviruses that cause SARS and MERS.
The first COVID-19 patient diagnosed in the United States—a young man in Snohomish county in Washington—was given remdesivir when his condition worsened; he improved the next day, according to a case report in The New England Journal of Medicine (NEJM). A Californian patient who received remdesivir—and who doctors thought might not survive—recovered as well.
Chloroquine and Hydroxychloroquine
At a press conference, President Donald Trump called chloroquine and hydroxychloroquine a “game changer.” “I feel good about it,” Trump said. His remarks have led to a rush in demand for the decades-old antimalarials. Researchers in France have published a study in which they treated 20 COVID-19 patients with hydroxychloroquine. They concluded that the drug significantly reduced viral load in nasal swabs.
Ritonavir/Lopinavir
This combination drug, sold under the brand name Kaletra, was approved in the United States in 2000 to treat HIV infections. Abbott Laboratories developed lopinavir specifically to inhibit the protease of HIV, an important enzyme that cleaves a long protein chain into peptides during the assembly of new viruses. Because lopinavir is quickly broken down in the human body by our own proteases, it is given with low levels of ritonavir, another protease inhibitor, that lets lopinavir persist longer.
Pinapurihan ni Piers Morgan ang mga immigrants sa United Kingdom (UK) na gumagawa ng 'amazing job' para sa National Health Service o NHS sa panahon ngayon ng coronavirus pandemic.
Sa programa sa TV na 'Good Morning Britain', pinasalamatan ni Morgan ang mga immigrants lalong lalo na ang mga Filipino doctors at nurses sa UK na patuloy na nagseserbisyo para sa mga tinamaan ng COVID-19. Ayun pa sa kay Morgan, nagulat siya na malaman na ang nagtratrabaho sa kanya na Filipina ay may mga kaibigan na nagtratrabaho sa iba't ibang hospital sa National Health Service.
Ads
‘It’s worth bearing in mind when we talk about immigrants in this country, these are the immigrants currently saving people's lives. Coming here and actually enriching our country and doing an amazing job’ - @piersmorganpic.twitter.com/dAYcH9t095
"A lovely Filipino woman who works for me, Corinne, was talking to her friends on Zoom yesterday and she said that all of them are in the NHS. I had no idea. I didn't realise. All of her friends are in the NHS and I asked her 'what do they do?'
She sent me this list and I'm just going to say them because we forget about this extraordinary workforce that comes from all around the world to work for the NHS and I just want to give them a little shout out.
Erin, nurse manager at Guy's Hospital and Nightingale Hospital, Ayesha who is a senior staff nurse at the intensive care unit at Guy's and St Thomas' Hospital which is where Boris Johnson is.
Terifa and Venus, nurses at the infectious diseases team at Northwick Park Hospital. Princess Short who is a nurse at St Mary's Hospital. Louis who is a nurse at Queen Alexander Hospital in Portsmouth and the whole team at Cheston Allergy Department at St Mary's Hospital.
An amazing number of Filipinos work in our NHS and unsung heroes, like so many but I just wanted to give them a shout out right now. Just outstanding care.
It’s worth bearing in mind when we talk about immigrants in this country, these are the immigrants currently saving people's lives. Coming here and actually enriching our country and doing an amazing job. So thank you to all the Filipinos who are here and to every other immigrant who works in the NHS currently and I hope at the end of this we have perhaps a different sentiment and a different feeling about what immigration has done for this country."
Samantala narito ang pinakalatest na data about sa Corona Virus ng UK
The American Chemistry Council's (ACC) Center for Biocide Chemistries (CBC) has compiled a list of products that have been pre-approved by the U.S. Environmental Protection Agency
(EPA) for use against emerging enveloped viral pathogens and can be used during the 2019 novel coronavirus (COVID-19) outbreak.
This product list is not exhaustive but can be used by
business owners, health professionals, and the public to identify products suitable for use during the COVID-19.
The information in this document is being provided as a public service. Persons receiving this information must make their own determination as to a product's suitability prior to use based on product
labeling.
Ads
This Novel Coronavirus (COVID-19)—Fighting Products are listed on American Chemistry website and are duly approved against emerging enveloped viral pathogens and can be used during the 2019 novel coronavirus (COVID-19) outbreak. We are getting the list from the Dept of Health of the list if there's any for products sold locally that can also help fight viruses.
Ads
Sponsored Links
Ready to Use or DILUTABLE Products Against COVID19. Here is the list:
Fabuloso Complete Disinfecting Wipes Colgate-Palmolive
Company
Germ Freak Bissell Homecare, Inc.
Handyclean™ Steridol Wipes Diamond Wipes International, Inc.
I7 DISINFECTANT WIPES Ecolab Inc/Kay Chemical Co.
INTERvention Farm Animal Care Disinfectant Cleaner &
Deodorizer Ready to Use Wipes
LCP BROAD SPECTRUM GERMICIDAL & DISINFECTANT WIPES LOR
Cleaner Products
Monk Disinfectant Wipes Dreumex USA, Inc.
MULTI-PURPOSE DISINFECTING WIPES Ecolab Inc
NASSCO PRO SERIES 88 BROAD SPECTRUM GERMICIDAL &
DISINFECTANT WIPES
NCLwipes Disinfectant Wipes Lemon Fresh National Chemical
Laboratories, Inc.
NCLwipes Disinfectant Wipes Waterfall Fresh National
Chemical Laboratories, Inc.
Optim 1 Wipes SciCan Ltd.
Optim 33 Tb Wipes SciCan Ltd.
Oxivir 1 Wipes Diversey, Inc.
OXIVIR™ WIPES Diversey, Inc.
Pathos II Disinfectant Wipes Share Corporation
Peroxigard Wipes One-Step Disinfectant Cleaner and
Deodorizer
PREempt Wipes Virox Technologies, Inc.
PURELL Foodservice Surface Sanitizing Wipes GOJO Industries,
Inc.
PURELL Professional Surface Disinfectant Wipes GOJO
Industries, Inc.
Rejuvenate Ready To Use Wipes One-Step Disinfectant Cleaner
REScue Wipes One-Step Disinfectant Cleaner & Deodorizer
Virox Technologies, Inc.
Sani-Cloth Prime Germicidal Disposable Wipe Professional
Disposables International,
SCRUBS® MEDAPHENE® Plus Disinfecting Wipes ITW Pro Brands
SONO Disinfecting Wipes Advanced Ultrasound Solutions, Inc.
SONO Ultrasound Wipes Advanced Ultrasound Solutions, Inc.
Spec4 Disinfectant Wipes Total Solutions
SSS TRIPLE S DISINFECTANT WIPES Triple S
TouchPoint Plus Disinfectant Wipes Innocore Sales &
Marketing
Wipes Plus Disinfecting Wipes 1 Progressive Products, LLC.
As a public service, US CBC is maintaining this list of antimicrobials that have proven to be effective against stronger pathogens, such as norovirus
or ebola. By publishing and maintaining this open list, CBC relieves federal, state, and local health officials’ resources in order to focus on other
aspects of the important effort to limit the spread of this new disease. Listing is voluntary and compliance with EPA’s “emerging viral pathogen”
guidance for antimicrobial products is verified by CBC. CBC will be working with federal and state officials to disseminate the list and make it
accessible to all those who need to be in the know.
